--- 
layout: single
title: TPE
---

# dosing levels 1-1.5

Daga Ruiz D, Fonseca San Miguel F, González de Molina FJ, Úbeda-Iglesias A, Navas Pérez A, Jannone Forés R. Plasmapheresis and other extracorporeal filtration techniques in critical patients. Med Intensiva. 2017 Apr;41(3):174-187. English, Spanish. doi: 10.1016/j.medin.2016.10.005. Epub 2017 Jan 3. PMID: 28062169.

Cervantes CE, Bloch EM, Sperati CJ. Therapeutic Plasma Exchange: Core Curriculum 2023. Am J Kidney Dis. 2023 Apr;81(4):475-492. doi: 10.1053/j.ajkd.2022.10.017. Epub 2023 Feb 10. PMID: 36775691.

Zhang L, Zhao XY, Guo SY, Jiang J, Wang G, Weng YB. An inquiry into the treatment of sepsis using plasma exchange therapy: A systematic review and meta-analysis. Int Wound J. 2023 Aug;20(6):1979-1986. doi: 10.1111/iwj.14059. Epub 2023 Jan 30. PMID: 36717980; PMCID: PMC10332988.

Carsten Hafer, Jan T. Kielstein, Pro: High dose of therapeutic plasma exchange—mind the gap!, Nephrology Dialysis Transplantation, Volume 32, Issue 9, September 2017, Pages 1457–1460, https://doi.org/10.1093/ndt/gfx084

# Sepsis, Septic Shock

Hadem J, Hafer C, Schneider AS, Wiesner O, Beutel G, Fuehner T, Welte T, Hoeper MM, Kielstein JT. Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients. BMC Anesthesiol. 2014 Apr 7;14:24. doi: 10.1186/1471-2253-14-24. PMID: 24708653; PMCID: PMC3986467.

Schmidt JJ, Asper F, Einecke G, Eden G, Hafer C, Kielstein JT. Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis. BMC Nephrol. 2018 Jan 15;19(1):12. doi: 10.1186/s12882-017-0803-3. PMID: 29334938; PMCID: PMC5769505.

# DLT/Phase I/Dose Escalation

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18. PMID: 27063978.

Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15. PMID: 29141948; PMCID: PMC5790128.

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. PMID: 28434648; PMCID: PMC7539326.

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17. PMID: 29040030; PMCID: PMC5946731.

van Zweeden AA, van der Vliet HJ, Wilmink JW, Meijerink MR, Meijer OW, Bruynzeel AM, van Tienhoven G, Giovannetti E, Kazemier G, Jacobs MA, Verheul HM. Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clin Cancer Res. 2015 Oct 15;21(20):4569-75. doi: 10.1158/1078-0432.CCR-14-3364. Epub 2015 Jun 8. PMID: 26056353.

Jenkin D, Ritchie AJ, Aboagye J, Fedosyuk S, Thorley L, Provstgaad-Morys S, Sanders H, Bellamy D, Makinson R, Xiang ZQ, Bolam E, Tarrant R, Ramos Lopez F, Platt A, Poulton I, Green C, Ertl HCJ, Ewer KJ, Douglas AD. Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. Lancet Microbe. 2022 Sep;3(9):e663-e671. doi: 10.1016/S2666-5247(22)00126-4. Epub 2022 Jul 27. PMID: 35907430; PMCID: PMC7614839.

Findling RL, Kauffman RE, Sallee FR, Carson WH, Nyilas M, Mallikaarjun S, Shoaf SE, Forbes RA, Boulton DW, Pikalov A. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol. 2008 Aug;28(4):441-6. doi: 10.1097/JCP.0b013e31817dd520. PMID: 18626272.

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. PMID: 32450106; PMCID: PMC7255193.

# SAP/Protocol

https://cdn.clinicaltrials.gov/large-docs/27/NCT01596127/Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/27/NCT01596127/SAP_001.pdf
https://clinicaltrials.gov/study/NCT01596127
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
- DLT is defined as a clinically significant adverse event 


https://clinicaltrials.gov/submit-studies/prs-help/prs-guided-tutorials

Guidelines for Therapeutic Plasma Exchange in Critical Care, University Hospitals Sussex, NHS Foundation Trust
https://docslib.org/doc/8040606/guidelines-for-therapeutic-plasma-exchange-in-critical-care

David, S., Russell, L., Castro, P., van de Louw, A., Zafrani, L., Pirani, T., Nielsen, N. D., Mariotte, E., Ferreyro, B. L., Kielstein, J. T., Montini, L., Brignier, A. C., Kochanek, M., Cid, J., Robba, C., Martin-Loeches, I., Ostermann, M., Juffermans, N. P., & Nine-I investigators (2023). Research priorities for therapeutic plasma exchange in critically ill patients. Intensive care medicine experimental, 11(1), 26. https://doi.org/10.1186/s40635-023-00510-w



# Examples

Dose Escalation Study Design Example (With Results) - https://cdn.clinicaltrials.gov/documents/trainTrainer/Dose-Escalation-Design-Answer-Key.pdf

https://cdn.clinicaltrials.gov/documents/trainTrainer/Dose-Escalation-Design-Fiction-Manuscript.pdf
https://cdn.clinicaltrials.gov/large-docs/53/NCT02954653/SAP_001.pdf

Pallmann, P., Wan, F., Mander, A. P., Wheeler, G. M., Yap, C., Clive, S., Hampson, L. V., & Jaki, T. (2020). Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical trials (London, England), 17(2), 147–156. https://doi.org/10.1177/1740774519890146

https://biostatsandtrials.wordpress.com/2020/08/18/rule-based-dose-escalation-design-phase-i-trial-3-3-design/


https://clinicaltrials.gov/study/NCT03646188

https://clinicaltrials.gov/study/NCT02296242

https://clinicaltrials.gov/study/NCT01277146

https://clinicaltrials.gov/study/NCT03310008
https://clinicaltrials.gov/study/NCT02092909



